AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03946527
Drug: Lanreotide
RxNorm normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive lanreotide 120 mg deep subcutaneous injection every 4 weeks (±7 days) for 52 weeks, followed by an extension phase in which all patients will continue to receive lanreotide 120 mg injection every 4 weeks (±7 days) if there is no evidence of disease progression.
Trial: NCT04614363
Drug: 68Ga-PSMA
RxNorm normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects enrolled in the study will receive a single IV dose of 3-7 mCi of 68 Ga-PSMA (study drug) followed by PET/CT imaging for detection of tumor location.
Trial: NCT02992288
Drug: Neladenoson bialanate (BAY1067197)
RxNorm normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg orally once daily for 20 weeks
Trial: NCT02992288
Drug: Neladenoson bialanate (BAY1067197)
RxNorm normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg orally once daily for 20 weeks
Trial: NCT02992288
Drug: Neladenoson bialanate (BAY1067197)
RxNorm normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg orally once daily for 20 weeks
Trial: NCT02992288
Drug: Neladenoson bialanate (BAY1067197)
RxNorm normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg orally once daily for 20 weeks
Trial: NCT02992288
Drug: Neladenoson bialanate (BAY1067197)
RxNorm normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg orally once daily for 20 weeks
Trial: NCT00023777
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ind: 200 mg/m2/d continuous IV days 1-7 consol: 200 mg/m2/d continuous IV days 1-5
Trial: NCT00023777
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ind and consol: 45 mg/m2/d continuous IV days 1-3
Trial: NCT00456846
Drug: ABI-007
RxNorm normalized name: ABI-007 COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg/m\^2 ABI-007 weekly for 3 weeks followed by 1 week rest
Trial: NCT03505762
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03505762
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02560805
Drug: Sodium Nitroprusside (SNP)
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.
Trial: NCT02560805
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus
Trial: NCT02560805
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan will be administered as 25 mg taken orally, once a day for to 8 to 14 weeks.
Trial: NCT02560805
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol will be administered as 25 mg taken orally, once a day for to 8 to 14 weeks.
Trial: NCT04347122
Drug: Tranexamic Acid (TXA)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention groups will receive TXA 1g TXA IVPB 10 minutes prior to incision and a second dose of 1g IVPB at the time of closure.
Trial: NCT02856568
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02856568
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02856568
Drug: Ricolinostat
RxNorm normalized name: Ricolinostat
DrugBank: Ricolinostat (DB12376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01684930
Drug: Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training
DrugBank: Beet (DB10640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
Trial: NCT02345265
Drug: Cediranib Maleate
RxNorm normalized name: maleate
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02345265
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00003042
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003042
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003042
Drug: mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003042
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00003042
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04214990
Drug: Aspirin 100mg
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily aspirin 100 mg for 5 years
Trial: NCT05581758
Drug: AMG 510
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT03793478
Drug: Quizartinib
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Administered orally once daily starting on Day 6 and continuing through Day 28;~Optional low intensity consolidation with chemotherapy:~Administered orally once daily starting on Day 1 and continuing through Day 28
Trial: NCT03793478
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m\^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)
Trial: NCT03793478
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/m\^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care);~Optional high intensity consolidation with chemotherapy and quizartinib:~500 mg/m\^2/day as a continuous 96-hour IV infusion on Days 1 through 4;~Optional low intensity consolidation with chemotherapy:~75 mg/m\^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18
Trial: NCT03793478
Drug: Intrathecal (IT) triple chemotherapy prophylaxis
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site
Trial: NCT03793478
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Optional high intensity consolidation with chemotherapy and quizartinib:~100 mg/m\^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5
Trial: NCT03465592
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT04558125
Drug: TNKase
RxNorm normalized name: TNKase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenecteplase (0.25 mg/kg) supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
Trial: NCT04558125
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants must also receive standard of care anticoagulation therapy.
Trial: NCT01185236
Drug: atorvastatin 20mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin 20mg once daily for 12weeks
Trial: NCT00418678
Drug: Cesamet
RxNorm normalized name: Cesamet
DrugBank: Nabilone (DB00486)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg BID on Days 2-5.
Trial: NCT00801957
Drug: tacrolimus ointment 0.03%
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical application
Trial: NCT00801957
Drug: hydrocortisone acetate ointment 1%
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: topical application
Trial: NCT00430014
Drug: Atiprimod
RxNorm normalized name: Atiprimod
DrugBank: Atiprimod (DB05513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
Trial: NCT01328886
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: omalizumab lyophilized 150 mg injection
Trial: NCT03130738
Drug: 7-Day Miconazole Oil (Miconazole 2%)
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
Trial: NCT03130738
Drug: 14-Day Miconazole Oil (Miconazole 2%)
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
Trial: NCT00043316
Drug: interferon gamma-1b
RxNorm normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 or 1000 mcg, inhalation, 3x per week
Trial: NCT03057938
Drug: 18F-Florbetaben (FBB)
RxNorm normalized name: florbetaben (18F)
DrugBank: Florbetaben F-18 (DB09148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive a single intravenous dose of 300 MBq of FBB followed by PET scan.
Trial: NCT03150329
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03476642
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection of 20mL of 0.5% Ropivacaine at the left or right T5 transverse process
Trial: NCT00915746
Drug: JNJ-31001074; ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03982121
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 240 mg
Trial: NCT03982121
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 5 or 10 or 25 mg
Trial: NCT03982121
Drug: GLA-SE
RxNorm normalized name: GLA-SE
DrugBank: G100 (DB17244)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLA-SE 1 or 2 or 5 or 10 or 20 μg
Trial: NCT00347022
Drug: Xenetix
DrugBank: Iobitridol (DB12407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of iodine/ml
Trial: NCT00347022
Drug: Visipaque
RxNorm normalized name: Visipaque
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 270 mg of iodine/ml
Trial: NCT04125927
Drug: Mercaptamine
RxNorm normalized name: Mercaptamine
DrugBank: Cysteamine (DB00847)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be treated with 1 drop in each eye 4 times a day, at the same dose and regimen than the one indicated in adults and children from 2 years of age.
Trial: NCT04225195
Drug: Amphotericin B cholesteryl sulfate complex for injection(ABCD)
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IC patients will only receive intravenous treatment with ABCD, with the longest course of treatment up to 42 days. ABCD will be administered once a day at a dose of 3-4 mg/kg. Visit plan: screening period (D-4 to D-1), baseline period (D1), treatment period and follow-up period (14±3days after the end of the last dose of ABCD).~IA patients will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. The total course of treatment should be at least 6 to 12 weeks. ABCD dosing regimen will be the same as that for IC patients. Visiting plan: screening period (D-4to D-1), baseline period (D1), treatment period and follow-up period.
Trial: NCT04965701
Drug: Osimertinib 80 MG
RxNorm normalized name: osimertinib 80 MG
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib is administered according to clinical practice at the recommended dose of 80 mg, orally, once a day.
Trial: NCT04069234
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ticagrelor 60 mg BID for 30 days
Trial: NCT04069234
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: clopidogrel 75mg OD for 30 Days
Trial: NCT00743834
Drug: Luvox CR
RxNorm normalized name: Luvox CR
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
Trial: NCT03809702
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
Trial: NCT01813136
Drug: Continuous pazopanib (Arm A)
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
Trial: NCT01813136
Drug: Intermittent pazopanib (Arm B)
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression
Trial: NCT03646916
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gluco-corticosteroid
Trial: NCT02766699
Drug: EGFR(V)-EDV-Dox
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
Trial: NCT00266331
Drug: Reduced glutathione
RxNorm normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01097057
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01097057
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01097057
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01097057
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT00821886
Drug: Ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
Trial: NCT00821886
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
Trial: NCT00821886
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
Trial: NCT01393925
Drug: parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
Trial: NCT03606018
Drug: Insulin Lispro Mix 25
RxNorm normalized name: insulin lispro 25 UNT/ML
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: insulin lispro biphasic in doses 0.4 ME/kg
Trial: NCT04318015
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatment will be administered orally.
Trial: NCT00771420
Drug: CAM-3001
RxNorm normalized name: CAM-3001
DrugBank: Mavrilimumab (DB12534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
Trial: NCT00771420
Drug: CAM-3001
RxNorm normalized name: CAM-3001
DrugBank: Mavrilimumab (DB12534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed at 0.1mg/kg.
Trial: NCT00771420
Drug: CAM-3001
RxNorm normalized name: CAM-3001
DrugBank: Mavrilimumab (DB12534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed at 0.3mg/kg
Trial: NCT00771420
Drug: CAM-3001
RxNorm normalized name: CAM-3001
DrugBank: Mavrilimumab (DB12534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed at 1.0 mg/kg.
Trial: NCT00771420
Drug: CAM-3001
RxNorm normalized name: CAM-3001
DrugBank: Mavrilimumab (DB12534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed at 3.0 mg/kg.
Trial: NCT00771420
Drug: CAM-3001
RxNorm normalized name: CAM-3001
DrugBank: Mavrilimumab (DB12534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed at 10 mg/kg.
Trial: NCT01658527
Drug: Orteronel
RxNorm normalized name: Orteronel
DrugBank: Orteronel (DB12066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.~Upon progression, patient may stay on study medication until the initiation of a new therapy
Trial: NCT01658527
Drug: Bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
Trial: NCT02076646
Drug: L19IL2 - Ph I
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).
Trial: NCT02076646
Drug: L19IL2 at RD - Ph II
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.
Trial: NCT02076646
Drug: DTIC
RxNorm normalized name: DTIC
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).